InterCure (INCR.TA) Stock Price
InterCure Price
InterCure (INCR.TA) Stock | ISIN IL0011063760 | WKN A1CZA8. The current InterCure stock price is 304 ILS (2026). Revenue is 574 M ILS. Net income is 78.13 M ILS. The P/E ratio is 178.47. Market capitalization is 13.94 B ILS. InterCure operates in the Health sector.
Over the last 19 years InterCure grew revenue by 14.3% annually, reaching 238.85 M ILS. Earnings per share have declined at 24.6% per year over the last 10 years. For InterCure, the net margin of -28.4% is up versus -57.2% a few years ago.
InterCure stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of InterCure over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how InterCure stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing InterCure's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | InterCure Price |
|---|
InterCure Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
InterCure Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (M ILS) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M ILS) |
| NET INCOME (M ILS) |
| NET INCOME GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e |
|---|---|---|---|---|---|---|---|
| 8 | 65 | 219 | 388 | 355 | 238 | 404 | 574 |
| – | 712.5 | 236.92 | 77.17 | -8.51 | -32.96 | 69.75 | 42.08 |
| 12.5 | 46.15 | 43.38 | 40.72 | 30.42 | 14.71 | 8.66 | 6.1 |
| 1 | 30 | 95 | 158 | 108 | 35 | 35 | 35 |
| -5 | -37 | 4 | 44 | -61 | -67 | 27 | 78 |
| -58.33 | 640 | -110.81 | 1,000 | -238.64 | 9.84 | -140.3 | 188.89 |
| 23.3 | 26.15 | 46.92 | 45.35 | 45.57 | 45.87 | 45.87 | 45.87 |
| – | – | – | – | – | – | – | – |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales InterCure generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue InterCure retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare InterCure's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares InterCure has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against InterCure's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
InterCure stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
InterCure Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
InterCure business model & stock analysis
InterCure SWOT Analysis
Strengths
InterCure Ltd has a strong market presence and brand recognition in the healthcare industry.
The company is backed by a highly skilled and experienced management team.
InterCure has a diverse product portfolio, catering to different segments of the healthcare market.
Weaknesses
InterCure faces stiff competition from other established players in the market.
The company's reliance on a few key suppliers puts it at risk of supply chain disruptions.
InterCure's geographic presence is limited to a few regions, hindering its global expansion opportunities.
Opportunities
InterCure can leverage advancements in technology to develop innovative healthcare solutions.
The growing demand for healthcare services presents an opportunity for InterCure to expand its customer base and market share.
Strategic partnerships and collaborations can help InterCure penetrate new markets and reach a wider audience.
Threats
InterCure faces regulatory uncertainties, which could impact its product development and commercialization processes.
Economic downturns and fluctuations in healthcare spending pose a threat to InterCure's financial performance.
Competitive pricing and cost pressures in the healthcare industry can affect InterCure's profitability.
InterCure Segments
InterCure Revenue by Segment
3 Years
Max
Details
InterCure Eulerpool Fair Value
InterCure historical P/E ratio, EBIT multiple, and P/S ratio
InterCure annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
InterCure shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
InterCure Earnings Estimates
InterCure Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 11/15/2022 | 0.26ILS | 108 MILS | 2022 Q3 |
| 5/16/2022 | 0.18ILS | 92.57 MILS | 2022 Q1 |
| 4/6/2022 | 0.14ILS | 77.03 MILS | 2021 Q4 |
| 11/16/2021 | 0.15ILS | 59.25 MILS | 2021 Q3 |
| 8/16/2021 | 0.14ILS | 39.58 MILS | 2021 Q2 |
InterCure shareholder structure
| % | Name |
|---|---|
31.03403% | |
4.11229% | |
0.46327% | |
0.23738% | |
0.21207% | |
0.10661% | |
0.08953% | |
0.06302% | |
0.04914% | |
0.03756% |
InterCure Executives and Management Board
Mr. Ehud Barak
(81)Chairman of the Board · since 2018
Mr. Alexander Rabinovitch
(51)Chief Executive Officer, Director · since 2018
Mr. Amos Cohen
(42)Chief Financial Officer
Mr. Rami Levy
Chief of Operation - Canndoc’s
Mr. Ori Mimon
Co-Chief Executive Officer of Cannolam Ltd
Frequently asked questions about InterCure
InterCure Ltd is a leading company in the healthcare sector. The business model of InterCure revolves around the development and commercialization of innovative medical solutions to improve patient outcomes. With a strong focus on research and development, InterCure aims to provide advanced therapeutic solutions in areas such as respiratory, cardiovascular, and sleep disorders. The company's commitment to excellence and cutting-edge technology enables it to meet the evolving healthcare needs of individuals worldwide. With a customer-centric approach and a dedication to improving quality of life, InterCure Ltd stands out as a prominent player in the healthcare industry.
InterCure stock
InterCure Peer Group
InterCure Ticker
InterCure FIGI
All fundamentals and in-depth analysis of InterCure
Our stock analysis for InterCure Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of InterCure Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.